This article is more than 5 years old. Information may no longer be current.
LaserSight receives FDA clearance and patent
WINTER PARK, Fla. — LaserSight Inc. received notification from the Food and Drug Administration (FDA) that the company may begin commercial distribution of its AstraMax diagnostic workstation. The company also received a notification of allowance from the U.S. Patent and Trademark Office for a patent application related to its AstraMax technology. Also, the company provided an update on the status of the FDA approval for utilizing its LaserScan LSX precision beam scanning laser system to treat astigmatism.
In December 2000 the company filed an additional premarket approval supplement requesting that the LSX be approved to treat myopia and myopic astigmatism utilizing the LASIK procedure. LaserSight subsequently received notification from the FDA that the FDA had completed its initial review and determined that the additional premarket approval supplement for LASIK was sufficiently complete to permit review.
The notice of allowance from the U.S. Patent and Trademark Office is for a patent related to its AstraMax technology. When issued, this patent will cover a method for simultaneous automatic measurement of the anterior and posterior corneal surfaces, corneal thickness and optical aberrations of the eye. The invention utilizes a wave front measurement technique that incorporates multiple resolution micro-lens arrays and a keratometric target.